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The efficacy and safety of two different doses of caffeine 
in respiratory function of preterm infants 
 
 
Abstract 
Background: Caffeine is widely used for prevention of apnea and helps successful 
extubation from mechanical ventilation. It facilitates the transition from invasive to 
noninvasive support and reduces duration of continuous positive airway pressure (CPAP) 
in preterm infants. The optimum caffeine dose in preterm infants has not been well-studied 
in terms of benefits and risks. We compared efficacy and safety of once versus twice-daily 
caffeine dose in premature infants. 
Methods: This study was a randomized clinical trial conducted in Bu-Ali Sina Teaching 
Hospital, Sari. Patients with gestational age of <37 weeks were included. Both groups 
received 20 mg/kg loading dose of caffeine intravenously followed by maintenance dose 
of 5 mg/kg/day in group 1 or 2.5 mg/kg every 12 hours in group 2. Extubation failure, 
CPAP failure and possibly adverse reactions were evaluated. 
Results: The mean of gestational age and birth weight were 32.27±3.23 (weeks) and 
1824.5±702.54 (gr), respectively. The rate of extubation and CPAP failure and length of 
NICU stay were lower in twice-daily-group with no statistically significant difference. The 
means of O
2
 saturations on the first three days of caffeine therapy were higher in twice-
daily-group. Caffeine was generally safe and well tolerated. 
Conclusions: This study, which assayed short-term effects of caffeine, showed that twice 
daily caffeine maintenance dose was related to more benefits in facilitating extubation or 
prevention of CPAP failure in preterm infants. However, there was not statistically 
significant difference between two groups. 
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Respiratory distress syndrome (RDS) is generally seen in preterm infants. RDS in 
neonates is managed with the intention to supply interventions that enhance survival as 
well as lessen potential complications, such as the risk of broncopulmonary dysplasia 
(BPD) (1-3). Many of the patients require mechanical ventilation and may be ventilator 
dependent for several days or even many weeks. The patients who have apnea and poor 
respiratory drive need further time of mechanical ventilation. Prolonged mechanical 
ventilation is associated with several short-term and long-term complications such as 
barotrauma and the development of chronic lung disease, atelectasis, air leak syndrome, 
pneumonia, neurodevelopmental impairments and bronchopulmonary dysplasia (4, 5). 
Methylxanthines (MGs) have been used 25-years ago as the backbone of pharmacologic 
treatments of respiratory disorders in premature infants. MGs are still widely used to 
manage apnea and facilitate successful extubation from mechanical ventilation (6-8). The 
efficiency of caffeine, as a preferred methylxanthine, to stimulate respiration has been well 
proven.    
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Caffeine also, has significant favorable impact on 
neonatal morbidity such as BPD, patent ductus arteriosus 
ligation and so on. Useful effects, safety, efficacy, and cost-
beneficial use caffeine introduced as the ‘silver bullet’ in 
neonatology (9). The results of previous studies revealed that 
caffeine enhances respiratory muscle strength and lung 
function followed by easier weaning of mechanical 
ventilation in premature infants (10). Also, a rapid and 
sustained increase in diaphragmatic activity and tidal volume 
was reported in preterm infants followed by caffeine 
administration (11). Previous studies have shown that 
caffeine citrate was generally well tolerated by premature 
neonates in clinical trials and declined the incidence of apnea 
in this population compared with placebo.  
It has established treatment and found to be equally 
effective like theophylline but has an overall superior safety 
due to a wider therapeutic index (12). Additionally caffeine 
is related to superior outcomes due to its lower toxicity and it 
is a preferred drug for apnea in preterm infants with 
respiratory problems (13).  
In a large randomized clinical trial, it has proven that the 
use of caffeine in very low birth weight infants reduced the 
incidence of BPD and duration of continuous positive airway 
pressure (CPAP) with no short-term adverse effects (14). 
The infants were followed-up until the age of five after 
caffeine therapy and established its long-term safety (15). 
Another report in 2006 indicated that infants in the caffeine 
group had a shorter duration of CPAP and mechanical 
ventilation than those in the placebo group and have lower 
incidence of BPD (16).  
The assessment of long-term effects of caffeine therapy 
in neonates showed an improvement in survival rate with no 
disability in neurodevelopmental status at 18 to 21 months in 
premature infants (17). Several reviews about caffeine in the 
treatment of premature infant respiratory disorders 
confirmed the overall advantages of this drug and explained 
it as the drug of choice in this condition with some protective 
effects on the brain and lungs with few side effects (18-23). 
Additionally, based on the recent multicenter and 
observational study to assess the clinical use, outcome and 
safety profile of caffeine in  the treatment of apnea of 
prematurity (AOP), this drug was safe to use and the 
incidence of adverse drug reactions was low (24). In brief, 
caffeine has a significant function as a noninvasive 
respiratory support. It facilitates the transition from invasive 
to noninvasive support, reduces the duration of positive 
airway pressure support and decreases the risk of BPD in 
preterm infants. Nevertheless, the optimum caffeine dose in 
preterm infants with respiratory distress syndrome has not 
been well studied as well as heterogeneous reports on the 
optimal loading and maintenance dose of caffeine in several 
studies in terms of benefits and risks. Many investigations 
have been conducted about various dosing regimens in the 
improvement or prevention of respiratory disorders of 
premature infants (5, 25-31). These dosage regimens, 
although, have been associated with varying degrees of 
success.  
The current standard dosing regimen for caffeine citrate 
is 20 mg/kg (or 10 mg/kg as caffeine base) as a loading dose 
followed by 5mg/kg/day (or 2.5 mg/kg as caffeine base) as 
maintenance dose (32, 33). We hypothesized the 12-hour-
interval leading to the more stable plasma drug 
concentrations and improving patient's outcome compared to 
once-daily dosing. The aim of this study was to compare 
efficacy and safety of once versus twice-daily caffeine-dose 
in premature infants with respiratory distress syndrome.  
 
 
Methods 
This study was an open-label randomized clinical trial 
conducted at a neonatal intensive care unit in Bu-Ali Sina 
Teaching Hospital, Sari, Iran (between July 2015 and August 
2016). Study protocol was approved by the Research Ethics 
Committee of Mazandaran University of Medical Sciences, 
Sari, Iran. This trial was registered at IRCT.ir (reference 
number IRCT201510172342N4). All subjects' parents were 
informed about the nature and purpose of the study. This 
included an explanation of aims, methods, objectives, and 
potential hazards of the study and informed signed consent 
was obtained from their parents. The investigator explained 
to the parents that they were under no obligation to take part 
in the study and could withdraw at any time. Patients were 
included in the study if they had a gestational age of 26 to 37 
weeks, with evidence of respiratory distress syndrome that 
was diagnosed by a neonatologist and treated by caffeine 
therapy facilitating earlier weaning process from mechanical 
ventilation or undergoing CPAP therapy.  
The exclusion criteria were asphyxia, hypoglycemia, 
intracranial ventricular hemorrhage (IVH), major congenital 
anomaly and previous exposure to methylxanthine therapy. 
If the patient met the inclusion criteria, he/she was enrolled 
and randomly assigned to one of the two study groups. Both 
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groups received a 20 mg/kg loading dose (LD) of caffeine 
citrate that was administered intravenously over 30 minutes 
followed by a maintenance dose (MD) of 5 mg/kg every 24  
in group 1 or 2.5 mg/kg infused every 12-hour-interval in 
group 2 over 20 minutes. Demographic characteristics 
(gestational age, gender, birth weight, type of delivery and 
Apgar score at 1 and 5 minutes after birth, age at initiation of 
caffeine, duration of caffeine therapy, length of stay in 
NICU,  ventilator modality, primary RDS score, daily blood 
gas levels and routine laboratory tests) were recorded. 
Extubation failure, CPAP failure, duration of the ventilator 
and CPAP therapy for all patients were also registered as 
primary outcomes. In addition, an average of heart pulse rate 
and blood pressure based on the values registered in the daily 
sheets was recorded for all infants.  
The possible adverse drug reaction of caffeine including 
tachycardia, feeding intolerance, hyperglycemia or 
hypertension were also investigated in case they happen.  
Side effects and clinical worsening were used to assess 
safety and tolerability. The mentioned parameters were 
assessed since the time of caffeine therapy initiation until the 
infants treatment. All statistical analyses were conducted 
using SSPS Version 19 (SPSS Inc., Chicago, IL, USA) and a 
p-value ≤0.05% was considered statistically significant. 
Number and percent age are represented the qualitative 
variables and mean±SD displayed the quantitative variables. 
Continuous variables of two groups were compared using 
independent samples t-test, while qualitative variables were 
analyzed using chi-square test.  
 
 
Results 
1. Demographic and drug dosing data analysis: Forty-
seven patients were enrolled in the study protocol and forty 
of them fulfilled the study criteria. Seven patients were 
excluded, of these, two patients were due to hypoglycemia, 
one with IVH, two had congenital anomaly and another two 
because of death (figure 1). Half of the patients (50%) were 
girls, the mean of gestational age was 32.3±3.2 weeks weeks, 
the mean of birth weight was 1824.5±702.54 gr and the type 
of delivery in majority (92.5%) of patients was cesarean 
(c/s).  
Demographic and clinical characteristics of the neonates 
in two groups are presented in table 1. There were no 
significant differences in gender, gestational age, birth 
weight, type of delivery, Apgar scores at 1 and 5 minutes 
after birth, RDS score, surfactant therapy (INSURE) and age 
at the beginning of treatment of the two groups. The average 
length of stay in NICU was 17.8±18.5 days and duration of 
caffeine therapy on average was 5.33±2.95 days, however, 
we considered the first three days of caffeine therapy in our 
analyses for all the patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Diagram of the participants 
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Table1. Demographic and clinical characteristics of the patients in two study groups 
Subject 
All subjects 
(n=40) 
Group 1 
(n=20) 
Group 2 
(n=20) 
P-value 
Female/male 20.20 11.9 9.11 0.52 
GA at birth (week) 32.27±3.23 32.2±3.06 32.34±3.46 0.89 
BW(gr) 1824.5±702.54 1772±675.27 1877±742.5 0.64 
Vaginal /Cesarean delivery 3.3 1.19 2.18 0.54 
Apgar, 1 min/ Median(IQR) 9 (8-9) 9 (8-9) 9 (9-9) 0.32 
Apgar, 5 min/ Median(IQR) 10 (9-10) 10 (9-10) 10 (9.25-10) 0.86 
RDS score/ Median(IQR) 6 (4-7) 6 (4.25-7) 5.5 (4-7) 0.49 
Surfactant (INSURE) 19 (47.5) 12 (60) 7 (35) 0.11 
PNA at initiation of caffeine (day) 8.23±9.2 7.1±7.7 6.7±7.2 0.86 
GA:gestational age, BW: birth weight, Apgar1: Apgar score in 1th minutes after birth, Apgar5: Apgar score in 5th minutes after birth, RDS: 
Respiratory distress syndrome score at the time of admission, PNA: postnatal age. Group1: once daily, group2: two divided dosing per day of 
caffeine. 
 
2. Effect of caffeine dose on the respiratory status of 
patients: Twice a day compared to once daily dosing 
regimen of caffeine resulted in a reduction in failure of 
extubation and CPAP failure rate and length of NICU stay 
among preterm infants (14.7 VS 12 days, respectively), 
although they were not statistically significant. Nonetheless, 
there were no significant differences in the duration of 
mechanical ventilation, CPAP therapy and mortality rate 
between the two groups (table 2(.  
 
Table 2. Comparison of neonatal outcomes among 
preterm infants receiving caffeine either in-group 1 
(n=20) (once daily) or group 2 (n=20) (twice daily) 
 
Parameters* Group 1 Group 2 Pvalue 
Extubation failure** 8(40%) 6(30%) 0.50 
N-CPAP failure*** 5(25%) 4(20%) 0.70 
Rate of mortality 4(20%) 4(20%) 1 
Duration of mechanical 
ventilation (days) 
12.82±15.12 13.63±11.67 0.90 
Duration of CPAP 
(days) 
5.69±4.97 6.36±10.37 0.82 
Length of NICU stay 
(day) 
14.7±10.03 12±7.23 0.33 
 
* value are presented in (n(%) or mean±SD) 
**Extubation failure: (i) an inability to extubate from mechanical 
ventilation within 48 h of caffeine loading (ii) the use of 
reintubation within 7 days of commencing caffeine therapy  
***CPAP failure: SpO2<85%, PO2<50 mmHg, pH<7.2, PCO2>60 
mmHg. 
 
3. Blood gas levels change during the course of caffeine 
therapy: Arterial blood gas (ABG) parameters were 
measured daily for each patient and their mean values are 
presented in table 3. All pH values were in the normal range 
except the first day in group 1 that elevated to the normal 
range on the second day of treatment (from 7.33 to 7.37). In 
addition, all values of Pco2 and HCO3 in patients of group 2 
were in normal range compared to group1 during the first 3 
days of caffeine therapy. At any rate, these differences were 
not statistically significant. Most of the differences were 
seen in the values of the O
2
 saturation between two groups. 
 
Table 3. Comparison of blood gas values between the two 
groups in the first 3 days of treatment with caffeine. All 
values are displayed on (Mean±SD) 
 
Parameters Group 1 Group 2 Pvalue 
pH 
Day 1 7.33±0.1 7.37±0.08 0.21 
Day 2 7.37±0.12 7.37±0.06 0.85 
Day 3 7.37±0.16 7.39±0.12 0.68 
PCO2 (mmHg) 
Day 1 51.9±21.2 43.3±14.3 0.14 
Day 2 46.8±19.2 42.8±11.1 0.42 
Day 3 50.2±31.6 45.5±18.7 0.57 
HCO3 (mEq/l) 
 
Day 1 28.4±8.1 25.3±6.5 0.19 
Day 2 28.9±8.3 26.1±4.9 0.18 
Day 3 27.1±5.8 26.2±5.9 0.63 
O2 saturation 
(%) 
Day 1 89.9±15.1 93.8±15.5 0.42 
Day 2 89.1±11.2 95.2±7.4 0.049* 
Day 3 89.1±14.6 95.9±5.5 0.056 
*There was a significant difference in O2 saturation on day 2 
between two groups. 
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All of O
2
 saturation levels in neonates that received 
caffeine twice a day were higher compared to those with 
once-daily-dosing even the difference on the 2
nd
 day was 
significant (p<0.05). Furthermore, the value of O
2
 saturation 
on the 3nd day moved towards a meaningful trend (P<0.05). 
4. Safety and Tolerability: Heart rate, blood pressure, 
feeding intolerance and blood sugar of all infants were 
recorded daily based on the infants' laboratory tests or data in 
the NICU sheets. The mean values over the course of 
caffeine therapy have been shown in table 4. Hyperglycemia 
and hypertension episodes were lower in preterm infants that 
received caffeine twice a day compared to those with once-
daily-dose. Hypertension was the most frequently reported 
adverse effect (AE) that occurred in some cases over the 
treatment. The mean arterial pressure had the greatest 
difference between two groups of neonates with the trend 
toward statistical significance (p=0.07). 
Totally, intravenous administration of caffeine was 
generally safe and well tolerated. None of the patients had 
tachycardia during the study. Most of the AEs were reported 
as mild in severity, and no serious AEs were recorded. Eight 
deaths occurred during the study (4 cases in each group) of 
which they were not caffeine-related. 
 
Table 4. Frequency and type of adverse effects observed 
following administration of caffeine 
Pvalue Group2 Group1 Type of AE 
0.56 1 2 Feed intolerance 
0.10 21(38.9%) 33(61.1%) Hyperglycemia* 
0.22 35(43.2%) 46(56.8%) 
Systolic 
BP 
Hypertension** 
0.63 34(42.2%) 38(52.8%) 
Diastolic 
BP 
0.07 37 (39.4) 57(60.6%) MAP 
Blood glucose >125 mg/dl, **Systolic blood pressure >75 mmHg, 
Diastolic blood pressure >45 mmHg, MAP>55 mmHg 
 
Discussion 
Caffeine is one of the most currently used medications in 
the neonatal care units. Despite its widespread use in preterm 
infants, there has been little information about optimal dose 
in these patients. This clinical trial was designed to assess 
the efficacy, safety and short-term effects of two different 
dosing regimen of caffeine citrate in periextubation 
management of preterm infants with gestational age <37 
weeks. In sum, 40 preterm infants were included in this 
study and received either caffeine 2.5 mg/kg twice daily or 5 
mg/kg once daily. All of them received caffeine 20 mg/kg as 
a loading dose in the beginning of treatment. The results 
indicated that caffeine improved the respiratory function of 
neonates in two study groups. There was a trend to a benefit 
for patients receiving caffeine 2.5 mg/kg twice daily 
compared to the 5 mg/kg once daily dosing; yet there was 
not statistically significant difference. The rate of extubation 
and CPAP failure and length of NICU stay were lower in the 
twice-daily-group than once-daily-group, too. In addition, 
the means of O
2
 saturations on the first three days of 
treatment with caffeine were higher in group 2 compared to 
group 1. Thus the mean difference of O
2
 saturation between 
two groups was meaningful on the second day (p<0.05) and 
a trend towards significant on the third day (p<0.05).  
Previous studies indicated the efficacy of caffeine in the 
improvement of respiratory function in preterm infants with 
low birth weight. Additionally, there are many reports of 
caffeine useful effects on the treatment or prevention of 
apnea in premature infants. Caffeine is an effective 
respiratory stimulant drug in the premature infants (26). This 
drug significantly decreases duration of mechanical 
ventilation and need for it (34). Caffeine led to a significant 
decrease of apnea in the treatment group as compared with 
the control group with no adverse effects during the study 
(35). Besides, this drug improves tidal volume ventilation 
and mean inspiratory flow mostly by stimulating central 
respiratory drive (36).  
A study has reported that the use of caffeine can lead to 
prevent apnea episodes that need intervention and also 
enhances the results of pneumogram (37). A randomized 
double-blind clinical trial was conducted by Steer et al. that 
compared three dosing regimens of caffeine (3, 15 or 30 
mg/kg) for periextubation control of premature infants. This 
trial revealed that the infants in higher dose group had lower 
apnea events through the week after extubation. Likewise, 
the short term safety of caffeine was endorsed (30). Other 
trials compared two different doses of caffeine (5 or 20 
mg/kg/day) for extubation of preterm infants that was 
showed short-term effects of higher-dose regimen in the 
periextubation days. A dose of 20 mg/kg/day was 
administered in this period eases extubation, declines the 
time of mechanical ventilation and decreases apnea events 
after extubation without the increase of short-term side 
effects (5). The results of a multicentre, randomized and 
controlled trial that compared two different dosing regimens 
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of caffeine in preterm infants showed that the high-dose of 
caffeine as (20 mg/kg/day) reduces the need for respiratory 
support versus the standard dose (5 mg/kg/day) with no 
adverse outcomes in two years of age (38).  
Extended caffeine therapy causes the lower rate and 
severity of intermittent hypoxia in premature infants (39). 
The preventive effect of caffeine on apnea has been proven 
when it is administered in high-risk premature infants (40). 
The prophylactic use of caffeine results in the lower rate of 
mortality or BPD and PDA with no adverse outcomes (41). 
It has also been shown the favorable effect of caffeine on the 
treatment of central apnea is via stimulated neural breathing 
(42). The results of a randomized controlled trial revealed 
that the administration of high dose caffeine (loading 40 
mg/kg then maintenance dose of 20 mg/kg/day) compared 
with low dose caffeine (loading 20 mg/kg then maintenance 
dose of 10 mg/kg/day) decreased the rate of extubation 
failure in ventilated infants and apnea episodes without 
serious adverse effects (28). Findings of a recent study that 
have compared two different doses of caffeine in treatment 
of primary AOP demonstrated that the patients in high 
caffeine doses (LD: 20 mg/kg and MD: 15 mg/kg/day) had 
more benefits than the low caffeine doses (LD: 20 mg/kg and 
MD: 5 mg/kg/day) with no further side effects (31). Besides, 
caffeine notably improved the early pulmonary function and 
decreased apnea (43).  
In the current study, lower frequency of short-term 
adverse effects of caffeine was observed in twice-daily-dose 
group compared to single-daily-dose group. This issue may 
be due to the stable concentrations and lower plasma peak 
levels of caffeine following the twice-daily-dose 
administration. Closely similar to our results, previous 
studies which compared different dosing regimens of 
caffeine determined that low dose caffeine was related to 
fewer side effects. For example after 10 mg/kg loading dose 
of caffeine, the maintenance dose of 5 or 2.5 mg/kg was 
administered to groups 1 and 2, respectively. The results 
indicated that caffeine significantly reduces the apnea 
episodes in both groups and the rate of adverse effects such 
as tachycardia and feeding intolerance in group 2 was 
notably lower than in group 1 (29). A 20 mg/kg followed by 
5 mg/kg/day caffeine citrate administered intravenously for 
10 days has been shown to be safe and effective for treating 
apnea in premature infants of gestational age 28–32 weeks 
(44). The results of this research showed a trend to a partial 
superiority efficacy for infants receiving a dose of 2.5 mg/kg 
twice daily compared to 5 mg/kg once daily. Despite more 
improvements in the clinical outcome of patients in group 2, 
no significant difference was observed between the two 
groups. It may result in meaningful outcomes if the drug use 
in a clinical trial has larger sample size. These beneficial 
effects in twice-daily maintenance dose group may be due to 
a more steady state plasma level of caffeine in infants.  
This study which assayed the short-term effects of 
caffeine therapy, concludes that twice versus once-daily 
caffeine maintenance dose was related to more benefits in 
facilitating extubation or prevention of CPAP failure in 
infants of born gestational age less than 37 weeks with no 
statistically significant difference between two groups. 
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